But you can’t use the secondary device as an effective ongoing management tool as it is only a Class I and a screening tool so is ineffective as it only indicates so you still have to consult a doctor.
Ann: Agreement with Ilara Health to sell ResAppDx in Kenya, page-83
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
